Pharma Leader Series: Top Stem Cell Technology Companies 2015-2025

LONDON, June 11, 2015 /PRNewswire/ --

Stem cell specialists for healthcare - discover what the future holds for those companies.
Who are the top stem cell developers and producers? And what are their sales outlooks? Visiongain's new report shows you their potentials from 2015. There you discover therapies, results, trends in research and development, opportunities and revenue forecasts.

That way you find data and analysis on cellular technologies transforming human medicine. Our study analyses 23 leading companies in the US, Europe, Israel and Asia-Pacific. There you hear how stem cell producers can progress and gain, discovering their potentials.

Please read on, then, to scan those organisations and find what revenue that fast-growing and potentially large market could generate in future. See what's possible.

Forecasts and other data to benefit your authority on those biotechnologies and applications
In our new study you find profiles of 23 prominent stem cell companies and analyses of their industry. You explore sales results, R&D advances and revenue forecasting. Explore, from 2015, those firms' capabilities, portfolios and commercial prospects.

There you also gain 55 tables, 29 charts and six interviews with the industry. Discover views of authorities from ReNeuron, Apceth, Pluristem, Gamida Cell, and others, on that business.

See now how you can benefit your research, analyses and decisions, also saving time and helping your influence and authority on that biotechnology. The following sections explain.

United States (US) - leading organisations and their potentials
First our study gives discussions, analyses and commercial outlooks for 10 US-based stem cell firms:

• Osiris Therapeutics
• NeoStem
• Orthofix
• NuVasive
• AlloSource
• RTI Surgical
• Vericel Corporation
• Bioheart
• Neuralstem
• Ocata Therapeutics.

To see a report overview please email Sara Peerun on [email protected]

There you hear what the future holds for those cellular biology companies, including research trends and some revenue predictions to 2025.

Our study then analyses Asian organisations, explaining that region's potential.

Stem cell specialists based in the Asia-Pacific region - what developments possible?
You also discover commercial outlooks for six top researchers, developers and producers of stem cells in Asia:

• Mesoblast
• Reliance Life Sciences
• Anterogen
• Pharmicell
• MEDIPOST
• Stempeutics.

Our analyses show possibilities for advancing technology and raising business performance, assessing where money lies. Also see revenue forecasting to 2025.

The report then analyses Europe and Israel, showing those countries' activities and potentials.

Companies based in Europe and Israel- what successes can they achieve?
Our analysis also shows you progress and prospects for seven European and Israeli companies:

• TiGenix
• Cardio3 BioSciences
• Apceth
• ReNeuron
• Gamida Cell
• Cell Cure Neurosciences
• Pluristem Therapeutics.

That work shows where sales growth can occur. Many opportunities remain in that industry, with high, expanding revenues possible from this decade. You also explore clinical testing and plans for launching products.

Our study also assesses that world industry, showing you its potential revenues from 2015 to 2025.

Predictions for the worldwide stem cells market - see that industry's sales potential
Our report also forecasts revenues to 2025 for the overall world stem cells industry and five submarkets:

• Central nervous system (CNS) uses
• Cardiovascular (CV) applications
• Cancer treatment (oncology)
• Other therapy using those biological agents
• Non-therapeutic cellular products using the technologies.

There you find overall revenues reaching $13.8bn in 2019, with high growth to 2025. Discover what the future holds for those technological advances and their providers.

You also examine forces driving and restraining that industry - social, technological, economic and political forces. And you assess strengths, weaknesses, opportunities and threats.

Technologies and issues shaping that industry and market - explore progress and potential
Our study explains those stem cell technologies and other forces influencing that market. There you explore developments and forces, including these:
• Regulations for that cellular research and technology, and its applications
• Embryonic stem cells - potentials in tissue repair and regenerative medicine
• Autologous and allogeneic agents, including T cell therapy
• Novel treatments for cancer and other applications, e.g. diabetes and bone growth, including progress of clinical trials and product launches.

And also these influences, among others:
• Umbilical cord blood - applications and approvals for that tissue and cell banking
• Regional distribution of the stem cell industry's 2014 revenues
• Non-therapeutic pharma applications - screening and toxicity studies in drug development.

There you also get interviews with companies, finding information to help you stay ahead on commercial progress, outlooks and future trends. That way, avoid missing out.

WaysPharma Leader Series: Top Stem Cell Technology Companies 2015-2025  helps
In particular, our new investigation gives you this knowledge to benefit your work:
• Profiles of 23 leading stem cell companies in North America, Europe, Israel and Asia - assess products, R&D, progress, results, strategies and alliances
• Revenues to 2025 for that overall market at world level and for five submarkets - discover potential sales, seeing those technologies' commercial prospects
• Competition, demands and opportunities - explore what affects the stem cells industry, finding what influences participants' sales and determines their futures
• Interviews with developers, producers and marketers - find what participants in that field think, say and do, helping you stay ahead in knowledge.

Information found nowhere else, benefiting your research, analyses and decisions
Our report gives independent data. There you gain competitive intelligence found only in that work, seeing where progress and money lie. You examine the commercial possibilities.

With that original analysis you're less likely to fall behind in information or miss opportunity. There see how you could save time and effort. So benefit your plans, decisions and influence, helping you gain advantages.

And by trying our new analysis on stem cells you explore trends, R&D and sales predictions. Avoid missing out - please get that report here now.

To see a report overview please email Sara Peerun on [email protected]

To request an exec summary of this report please email Sara Peerun at, [email protected] or call Tel: +44 (0) 20 7336 6100 or click on  http://goo.gl/wKgAaM

Organisations Mentioned in this Report 

Aastrom Biosciences (now called Vericel Corporation)
Advanced Cell Technology (now called Ocata Therapeutics)
Alkems
Allergan
AlloSource
American Academy of Pediatrics
Amgen
Amorcyte
Anterogen
Apceth
Arthrex
Athelos
Auriga Ventures
BaYi Brain Hospital
Biogenea-Cellgenea
Bioheart
BioTime
Blackstone Medical
California Institute of Regenerative Medicine (CIRM)
California Stem Cell Inc
Cardio3 BioSciences
Carolinas Cord Blood Bank (CCBB)
Casey Eye Institute
Cell Cure Neurosciences
Cellerix
CELLTREE
Cephalon
CHA Bio & Diostech
Cha General Hospital
Chinese Academy of Sciences
Chinese Ministry of Health
Chinese Ministry of Science and Technology
Cipla
CJ CheilJedang
Clal Biotechnologies Industries
Clinicaltrials.gov
ClinImmune Labs
Committee for Advanced Therapies (CAT)
Committee for Medicinal Products for Human Use (CHMP)
Corniche Group
CRISPR Therapeutics
Denali Ventures
Dong-A Pharmaceuticals Co.
Duke University School of Medicine
Elbit Imaging
Elbit Medical Technologies
Eli Lilly
Elsevier
European Commission
European Medicines Agency (EMA)
Forbion Capital Partners
Gamida Cell
Genetrix
Geron
Hadasit Bio-Holdings, Ltd (HBL)
Hadassah University Hospital
Harvard Medical School
Human Fertilisation and Embryology Authority (HFEA)
Human Stem Cells Institute
Indian Department of Biotechnology
International Society for Stem Cell Research (ISSCR)
Israel Healthcare Venture
Israel Stem Cell Society
Japanese Health Ministry
Japanese Institute of Biomedical Research
Japanese Ministry of Economy, Trade and Industry (METI)
JCR pharmaceuticals
Korean Food and Drug Administration (KFDA)
Korean Ministry of Food and Drug Safety (MFDS)
LifeCord
LifeSouth
Lincoln Park Capital Fund
Lonza
Mayo Clinic
MEDIPOST
Medtronic
Merck Millipore
Mesoblast
Musculoskeletal Transplant Foundation (MTF)
National Institute of Health and Care Excellence (NICE)
Nature
NeoStem
Neuralstem
New York Blood Center
New York Heart Association
Novartis
NuVasive
Ocata Therapeutics
Oregon Health and Science University
Orthofix
Osiris Therapeutics
Pharmicell
Phase III Medical Inc.
Pluristem Therapeutics
Progenitor Cell Therapy (PCT)
Reliance Group
Reliance Life Sciences
ReNeuron
Roche
RTI Surgical
Sanofi
Schepens Eye Research Institute
Singapore National Eye Centre
Society for Neuroscience
Society for Stem Cell Research (ISSCR)
SSM Cardinal Glennon Children's Medical Center
St. Louis Cord Blood Bank
StemGen
Stempeutics
Swedish Orphan Biovitrum AB (Sobi)
Teva Pharmaceutical Industries
The Lancet
TiGenix
UK Department of Health and the Medical Research Council
UK Medicines and Healthcare Products Regulatory Agency (MHRA)
United Nations Department of Economic and Social Affairs
United Therapeutics
University of Colorado Anschutz Medical Campus (AMC)
University of Colorado Cord Blood Bank
University of Kyoto
University of Wisconsin Alumni Research Foundation
US Congress
US Department of Defense (DOD)
US Federal Reserve
US Food and Drug Administration (FDA)
US National Academy of Sciences
US National Institute of Health
US Patent and Trademark Office
Vericel Corporation
Viacyte
Yonsei University

To see a report overview please email Sara Peerun on [email protected] or call Tel: +44 (0) 20 7336 6100

SOURCE Visiongain